Assignment history

Inventors

• Ge Wei (Halozyme Inc.)
• H. Michael Shepard (Halozyme Inc.)
• Qiping Zhao (Halozyme Inc.)
• Robert James Connor (Halozyme Inc.)

All inventors were likely employed by Halozyme Inc. (the original applicant) or its related entity Halozyme Therapeutics, Inc. at the time of the patent application filing in 2024, given the assignment records show them assigning their interests to Halozyme Therapeutics, Inc. on the same date as an inter-company transfer.

Original assignee

The original assignee, as indicated by the patent filing and Google Patents, is Halozyme Inc.. Halozyme Therapeutics Inc. (which appears to be closely related or the primary operating entity) is a biotechnology company focused on developing and commercializing oncology therapies and innovative drug delivery solutions. They ship products embodying the claims, specifically utilizing their proprietary ENHANZE® drug delivery technology, which employs a recombinant human hyaluronidase enzyme (rHuPH20) to enable subcutaneous administration of injectable biologics. Key approved products include Hylenex and Xyosted. Halozyme Therapeutics Inc. is currently an active, publicly traded company on NASDAQ under the ticker HALO.

Assignment timeline

• 2024-12-15 (executed) / recorded 2024-12-18 — Reel 065261/0074

  • Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST
  • Assignor: CONNOR, ROBERT JAMES; WEI, GE; ZHAO, QIPING; SHEPARD, H. MICHAEL
  • Assignee: HALOZYME THERAPEUTICS, INC.
  • Correspondent: GABRIELLA K. ROTHMAN, HALOZYME, INC., 11388 SORRENTO VALLEY ROAD, SAN DIEGO, CA 92121. This correspondent also appears on reel 065261/0071.
  • Context: Internal transfer of inventor rights to the operating company.

• 2024-12-15 (executed) / recorded 2024-12-18 — Reel 065261/0071

  • Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST
  • Assignor: HALOZYME THERAPEUTICS, INC.
  • Assignee: HALOZYME, INC.
  • Correspondent: GABRIELLA K. ROTHMAN, HALOZYME, INC., 11388 SORRENTO VALLEY ROAD, SAN DIEGO, CA 92121. This correspondent also appears on reel 065261/0074.
  • Context: Internal corporate restructuring/transfer from operating entity to IP holding entity.

Timeline diagram

timeline
    title Ownership of US 12264345
    2024 : Filed by Halozyme Inc
         : Inventors assign to Halozyme Therapeutics
         : Halozyme Therapeutics assigns to Halozyme Inc
    2025 : Issued to Halozyme Inc

NPE / troll-pattern signals

1. Shell-entity transfer — not present. While Halozyme, Inc. may function as an IP holding entity, it is directly related to Halozyme Therapeutics, Inc., which is a large operating company with commercial products and significant revenue. There is no indication of transfer to an unrelated licensing-only LLC.
2. Known asserter in the chain — not present. Halozyme Inc. and Halozyme Therapeutics, Inc. are not identified as known NPEs.
3. Repeat correspondent across the chain — present. Gabriella K. Rothman of Halozyme, Inc. is listed as the correspondent for both recorded assignments (Reel 065261/0074 and Reel 065261/0071). This recurrence, within the same company's transfers, confirms an internal legal process.
4. Cascading transfers — not present. There are two assignments recorded on the same date, both internal to the Halozyme corporate family, and not multiple consecutive transfers through chained, unrelated LLCs.
5. Pre-litigation transfer — not present. The assignments occurred prior to issuance and there is no indication of litigation immediately following these transfers.
6. Bankruptcy fire-sale — not present. Halozyme Therapeutics, Inc. is a financially active and growing public company.
7. Privateering — not present. There is no evidence of Halozyme transferring the patent to an NPE to assert on its behalf.
8. Defensive aggregator (anti-NPE) — not present. The patent remains within the Halozyme corporate structure, which is an operating company.

Verdict

Operating-company assertion
This verdict is based on the fact that the patent is currently owned by Halozyme, Inc., which is part of the Halozyme corporate family, a prominent biotechnology operating company that develops and commercializes products embodying the claimed technology, such as the ENHANZE® drug delivery platform. The assignments recorded (Reel 065261/0074 and Reel 065261/0071) represent internal transfers within the Halozyme corporate structure, common for managing intellectual property within a large operating entity. Halozyme Therapeutics Inc. is an active public company with commercial products and substantial revenue.
USPTO Assignment Center search for US12264345